Plasmid-encoded gene duplications of extended-spectrum β-lactamases in clinical bacterial isolates

• Published in: Frontiers in cellular and infection microbiology 2024-02, Vol.14, p.1343858-1343858
• Main Authors: Sobkowiak, Annika, Scherff, Natalie, Schuler, Franziska, Bletz, Stefan, Mellmann, Alexander, Schwierzeck, Vera, van Almsick, Vincent
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; antibiotic susceptibility; antimicrobial resistance; beta-Lactamases - genetics; Ceftazidime - pharmacology; Cellular and Infection Microbiology; Enterobacteriaceae - genetics; ESBL; Escherichia coli; Gene Duplication; Humans; Klebsiella pneumoniae; Microbial Sensitivity Tests; plasmid; Plasmids - genetics; transposons
• ISSN: 2235-2988; 2235-2988
• DOI: 10.3389/fcimb.2024.1343858

The emergence of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae is an urgent and alarming One Health problem. This study aimed to investigate duplications of plasmid-encoded ESBL genes and their impact on antimicrobial resistance (AMR) phenotypes in clinical and screening isolates. Multi-drug-resistant bacteria from hospitalized patients were collected during routine clinical surveillance from January 2022 to June 2023, and their antimicrobial susceptibility patterns were determined. Genotypes were extracted from long-read whole-genome sequencing data. Furthermore, plasmids and other mobile genetic elements associated with ESBL genes were characterized, and the ESBL genes were correlated to ceftazidime minimal inhibitory concentration (MIC). In total, we identified four cases of plasmid-encoded ESBL gene duplications that match four genetically similar plasmids during the 18-month surveillance period: five and three isolates. As the ESBL genes were part of transposable elements, the surrounding sequence regions were duplicated as well. In-depth analysis revealed insertion sequence (IS)-mediated transposition mechanisms. Isolates with duplicated ESBL genes exhibited a higher MIC for ceftazidime in comparison to isolates with a single gene copy (3-256 1.5-32 mg/L, respectively). ESBL gene duplications led to an increased phenotypic resistance against ceftazidime. Our data suggest that ESBL gene duplications by an IS-mediated transposition are a relevant mechanism for how AMR develops in the clinical setting and is part of the microevolution of plasmids.